Keith Woods: Yes, I mean, certainly James, I think the first thing we need to do is to see the data to see how we stack up in not only efficacy, but as we believe from the profile of the product we do think we’ll probably have an edge on safety and convenience. With all that being said, comparing it to MG is probably not a likely scenario. And that is because the IVIG companies, they can’t promote IVIG and MG, it’s off label. However, CIDP is their single largest indication and this is a satisfied market. I think that there is room for improvement and the possibility to disrupt if the data allows, but we’re going into a market where physicians and patients are satisfied with IVIG. So I would not use the MG as a proxy to the CIDP launch, but let’s wait and see those data.
Operator: Your next question comes from the line of Joon Lee from Truist. Your line is open.
Joon Lee: Hey, thanks for taking our questions. Keith has done a phenomenal job of VYVGART launch and conventionalism is that if it didn’t broke, you don’t fix it, but I totally understand Keith has personal reasons. Could you elaborate a bit more on what Ms. Karen Massey brings the cable and what aspects of her expertise you think is particularly well suited to further drive VYVGART uptake. I’m sure you had many qualified candidates to choose from. Thank you.
Tim Van Hauwermeiren: Thank you for joining us on the call. And as you correctly called out, this was a planned transition, right? So Keith is retiring and his aspiration is to spend more time with Family and serving on board, including continuing to be an adviser to our board as a participant in our commercial committee. I think with Karen, we have the right person at the right time for argenx. She brings global operational experience, she has successfully led launches in the nuro-inflammation space. Specifically, I referred to the OCREVUS launch where she accelerated an already successful launch. And then I think she has a proven track record of building innovative global nimble teams, exactly the type of teams which we need if we want to continue to be successful on the commercial side.
We also believe that Karen is going to be a great cultural fit. And I think the culture of the company is strong. And not only did we hire a great leader from a technical master point of view, we also think we have an excellent cultural fit. So you’re right. I mean, there was choice. And I’m extremely excited about Karen joining us on March 13. Thanks for the question.
Operator: Your next question comes from the line of Simon Baker from Redburn. Your line is open.
Unidentified Participant: Hi. This is asking questions on behalf of Simon Baker. Thanks for taking my questions. Two questions if I may. So the question one is, can you discuss the IP position for VYVGART beyond the March 2036 composition patent expiry, particularly on the subcutaneous formulation? And the question two is, can you give us an update on the European rollout of VYVGART? In which countries do you expect to begin selling in 2023? Thank you.
Tim Van Hauwermeiren: Could you repeat question one on patent life, please? I couldn’t hear it.
Joon Lee: Yes. So the question one is, can you discuss the IP position for VYVGART beyond March 2036, a compensation patent expiry, particularly on the subcutaneous formulation?
